An international team of researchers has uncovered a crucial mechanism that allows certain cancer cells to hide from the body’s immune defenses, a discovery that could reshape future cancer treatments. The study, led by scientists at Julius-Maximilians-Universität Würzburg (JMU) in collaboration with partners in the United States, reveals how the powerful cancer-driving protein MYC not only fuels tumor growth but also helps tumors remain undetected by the immune system.

A new epidemiological study reported today finds that consistent heavy alcohol consumption over a lifetime is associated with a significantly increased risk of colorectal cancer, particularly rectal cancer, while reducing or quitting drinking may lower that risk. The findings were published online in the peer-reviewed journal Cancer.

Syngene announced a significant extension of its long-standing collaboration with global biopharmaceutical leader Bristol Myers Squibb (BMS). The renewed strategic agreement will now continue through 2035, marking a new decade of deep partnership aimed at driving drug discovery, development, and commercialization.